

**Date: 14<sup>th</sup> August, 2024**

To,  
The Manager,  
Bombay Stock Exchange Limited,  
Department of Corporate Services  
P.J Towers, Dalal Street,  
Mumbai 400001

**Script Code: 540359**

**Sub: Outcome of Board Meeting**

Dear Sir/Madam,

pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. August 14, 2024 inter alia has considered and approved:

1. The Unaudited Financial Results of the Company for the quarter ended on June 30, 2024. The same has also been reviewed by the Audit Committee in its meeting held today.
2. B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter ended June 30, 2024 and the Board has also taken on record their Limited Review Report on the said Results.
3. Appointed Mr. Samsad Alam Khan, Practicing Company Secretary, Ahmedabad as Secretarial Auditor for Secretarial Audit of the company for F.Y. 2024-2025.
4. Appointed M/s B. A. Shah & Associates, Chartered Accountants, Rajkot as Internal Auditor for Internal Audit of the company for F.Y. 2024-2025.

The Board Meeting commenced at 6:00 PM and concluded at 6:30 PM

You are requested to kindly take the above information on your record.

Thanking you.

For **Parmax Pharma Limited**

*Bhakti*


**Bhakti Aghera**  
Company Secretary

Encl a/a

## Statement of Standalone Unaudited Results for the Quarter ended 30.06.2024

(in Rs.Thousands)

Sr. No.	Particulars (Refer Notes Below)	Quarter Ended (30.06.2024)	Preceding Quarter ended (31.03.2024)	Corresponding Quarter Ended (30.06.2023)	Previous year ended (31.03.2024)
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income from Operations</b>				
	(a) Revenue from operations	78163.00	42574.7	14001.43	110530.35
	(b) Other income	80.14	141.38	136.95	481.16
	<b>Total income from operations (net) (a+b)</b>	<b>78243.14</b>	<b>42716.08</b>	<b>14138.38</b>	<b>111011.50</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	61739.05	47650.89	2827.89	70292.73
	(b) Purchase of stock-in-trade	0	0	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-3085.71	-15010.35	1460.76	230.00
	(d) Employee benefits expense	7484.86	4988.82	7249.92	29107.93
	(e) Finance Costs	1126.16	1625.48	1217.14	6216.78
	(f) Depreciation and amortisation expense	3962.24	4068.95	4187.81	17116.70
	(g) Other expenses*	6893.34	12950.06	8983.79	44606.10
	<b>Total expenses</b>	<b>78119.94</b>	<b>56273.85</b>	<b>25927.32</b>	<b>167570.25</b>
3	<b>Profit/(Loss) from operations before exceptional items and tax (1-2)</b>	<b>123.20</b>	<b>-13557.77</b>	<b>-11788.94</b>	<b>-56558.74</b>
4	Exceptional Items	0	0	0	0
5	<b>Profit/ (Loss) before tax (3-4)</b>	<b>123.20</b>	<b>-13557.77</b>	<b>-11788.94</b>	<b>-56558.74</b>
6	Tax expense:				
	(1) Current tax	0	1290.50	0	
	(2) Deferred tax	0	344.03	0	946.47
7	<b>Net Profit / (Loss) for the period from continuing operations (5-6)</b>	<b>123.20</b>	<b>-14504.24</b>	<b>-11788.94</b>	<b>-57505.22</b>
8	<b>Profit/(loss) from discontinuing operations</b>				
9	Tax expense of discontinuing operations	0	0	0	0
10	<b>Profit/(loss) from Discontinuing operations (after tax) (8-9)</b>				
11	<b>Profit (Loss) for the period (7+10)</b>	<b>123.20</b>	<b>-14504.24</b>	<b>-11788.94</b>	<b>-57505.22</b>
12	Other Comprehensive Income		0	0	0
13	<b>Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period )</b>	<b>123.20</b>	<b>-14504.24</b>	<b>-11788.94</b>	<b>-57505.22</b>
14	<b>Paid-up equity share capital (Face Value Rs 10)</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>
15	<b>Earnings per share (for continuing operation) (of Rs. 10/- each ) (not annualised):</b>				
	(a) Basic	0.03	-3.88	-3.15	-15.37
	(b) Diluted	-	-	-	-



## PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

- Notes:**
1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on **14th August, 2024**.
  2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2024.
  3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
  4. Statement of Unaudited Financial Results of the company for the quarter ended 30th June, 2024 in the prescribed format under Schedule III of Companies Act, 2013
  5. The figures for the previous period have been regrouped wherever necessary.

Place Hadamtala (Rajkot)  
Date: 14.08.2024

FOR, PARMAX PHARMA LIMITED

*U. Gosalia*

Dr. Umang Alkesh Gosalia  
Managing Director



**PARMAX PHARMA LIMITED**

**Regd. Off. & Factory :** Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 - 36 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

**Correspondence Add.:** A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner

**Malay B Shah**

B.Com. F.C.A.

M. No. 159526

Partner

**Zarna M Shah**

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

### Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,  
**PARMAX PHARMA LIMITED**

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended **30th June 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14<sup>th</sup> August 2024**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

*Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there*

Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
RAJKOT- 360 001  
(GUJARAT)

Electronic Address:  
(O) 0281-2468261

(M) 09427564149  
(E) [bassrmco.office@gmail.com](mailto:bassrmco.office@gmail.com)

Or  
[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)



# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner

**Malay B Shah**

B.Com. F.C.A.

M. No. 159526

Partner

**Zarna M Shah**

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 14.08.2024



For **B. A. SHAH S R MEHTA & Co.**

Chartered Accountants

FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B. Shah".

**MALAY B SHAH**

Partner

M. No. 159526

**UDIN : 24159526BKFOSG8481**

Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
RAJKOT- 360 001  
(GUJARAT)

Electronic Address:  
(O) 0281-2468261

(M) 09427564149  
(E) [bassrmco.office@gmail.com](mailto:bassrmco.office@gmail.com)

Or  
[mbshah\\_31@hotmail.com](mailto:mbshah_31@hotmail.com)

**Date: 14<sup>th</sup> August, 2024**

To,  
The Manager,  
Bombay Stock Exchange Limited,  
Department of Corporate Services  
P.J Towers, Dalal Street,  
Mumbai 400001

Script Code: 540359

**SUBJECT: INTIMATION OF APPOINTMENT OF A SECRETARIAL AUDITOR OF THE COMPANY FOR THE FY 2024-25.**


Dear Sir/Madam,

In continuation to outcome of the Board Meeting dated **14<sup>th</sup> August, 2024** and pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that the company has appointed **Mr. SAMSAD ALAM KHAN**, Company Secretary, as a Secretarial Auditor of the company for the Financial Year 2024-25.

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2013 is enclosed herewith.

You are requested to take the above information on your record.

**For PARMAX PHARMA LIMITED**

  
**BHAKTI AGHERA**  
Company Secretary

**Encl a/a**

**Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**APPOINTMENT OF SECRETARIAL AUDITOR:**

Sr. No.	Particulars	Details
1	Name of Auditor	Mr. Samsad Alam Khan (M No. A28719, CP No. 13972)
2	Reason for Change viz. appointment, resignation, removal, death or otherwise;	Appointment as a Secretarial Auditor
3	Proposed Date of Appointment/ cessation & term of appointment;	Date of Appointment 14 <sup>th</sup> August, 2024 Term: For the Financial Year 2024- 2025
4	Brief Profile;	CS Samsad Alam Khan registered as a Practicing Company Secretary with Institute of Company Secretaries of India (ICSI) as an Associate Member. He is having experience of more than 10 Years in Company Law and FEMA Matters. Apart from above, he is engaged with the services relating to Various Conversions, Search and Status Report, Conduct of Secretarial Audit, Consultancy for IPO etc.  Further he engaged as a Secretarial Auditor of Various Companies listed on main board of Bombay Stock Exchanges.
5	Disclosure of relationships between directors.	Not Applicable

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax : +91-2827-270536 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals



**Date: 14<sup>th</sup> August, 2024**

To,  
The Manager,  
Bombay Stock Exchange Limited,  
Department of Corporate Services  
P.J Towers, Dalal Street,  
Mumbai 400001

**Script Code: 540359**

**SUBJECT: INTIMATION OF APPOINTMENT OF AN INTERNAL AUDITOR OF THE COMPANY FOR THE FY 2024-25.**


Dear Sir/Madam,

In continuation to outcome of the Board Meeting dated 14th August, 2024 and pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that the company has appointed **M/S B. A. SHAH & ASSOCIATES**, Chartered Accountants, as an Internal Auditor of the company for the Financial Year 2024-25.

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2013 is enclosed herewith.

You are requested to take the above information on your record.

**For Parmax Pharma Limited**

  
**Bhakti Aghera**  
**Company Secretary**

**Encl a/a**

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 Fax : +91-2827-270536 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

**Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

**APPOINTMENT OF INTERNAL AUDITOR:**

Sr. No.	Particulars	Details
1	Name of Auditor	B. A. Shah & Associates
2	Reason for Change viz. appointment, resignation, removal, death or otherwise;	Appointment as an Internal Auditor (FRN: 109493W)
3	Proposed Date of Appointment/ cessation & term of appointment;	Date of Appointment 14 <sup>th</sup> August, 2024 Term: For the Financial Year 2024- 2025
4	Brief Profile;	<p>B. A. Shah &amp; Associates, Chartered Accountants, is a well-established firm with a strong presence in the audit and assurance domain. Their rich experience, particularly in the banking sector, coupled with their commitment to quality and professionalism, makes them a trusted partner for clients seeking reliable financial services.</p> <p>Over four decades of experience in statutory audits for major public and private sector banks, Extensive internal audit and inspection experience across numerous large group of companies, Monitoring Restructured accounts under CDR, forensic audits and Valuation audits, Stock Audits, Information Systems Audits, etc.</p>
5	Disclosure of relationships between directors.	Not Applicable